Since
the 1950’s, many individuals suffering from major psychotic illness have been
able to substantially reduce their symptom burden with antipsychotic
medications.
The past few decades has experienced a transition away from first
generation dopamine D2 receptor agonists towards second generation
antipsychotic medication (SGA) seratonin 5H7-2a antagonists, referred to as
“atypical” antipsychotics, examples being Clozapine and Olanzapine. These
atypical antipsychotics are different in mechanism and unlike first generation
antipsychotics (FGA), they are less likely to cause parkinsonian symptoms and
have an increased efficacy in treating negative symptoms. Read more>>>>>>>>>>>>>




